Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00938145 · ClinicalTrials.gov registry record · NA

3 Tesla MRI in Patients With Bladder Cancer

A NA study of Bladder Cancer, sponsored by University of Cincinnati.

Active
Registry status
NA
Development phase
98
Enrollment target
1
Study location

NCT00938145: Active NA study of Bladder Cancer, sponsored by University of Cincinnati.

NCT00938145 is a NA study of Bladder Cancer that is active but no longer recruiting, run by University of Cincinnati. The registered enrollment target is 98 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00938145, a NA study of Bladder Cancer, is active but no longer recruiting, sponsored by University of Cincinnati.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
98 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: New diagnostic procedures, such as 3 Tesla magnetic resonance imaging (MRI), may help find bladder cancer and learn the extent of disease. PURPOSE: This clinical trial is studying how well 3 Tesla MRI works in finding cancer in patients with bladder cancer.

Conditions Studied

Bladder Cancer

Interventions

  • PROCEDURE Specimen Ultra-High field MRI
  • DRUG chemotherapy
  • PROCEDURE Cystectomy and Lymphadenectomy

Study Locations (1)

Ohio

  • Ohio State University Medical Center - Columbus

Trial Details

FieldValue
Enrollment Target 98 participants
Start Date 2009-07-08
Est. Completion 2026-12-31
Phase NA
University of Cincinnati

245 total trials

What the registry record for NCT00938145 still lists

NCT00938145 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 3 interventions - of which Specimen Ultra-High field MRI is the first listed.

NCT00938145 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT00938145 about?

NCT00938145 is a clinical study titled "3 Tesla MRI in Patients With Bladder Cancer". RATIONALE: New diagnostic procedures, such as 3 Tesla magnetic resonance imaging (MRI), may help find bladder cancer and learn the extent of disease. PURPOSE: This clinical trial is studying how well 3 Tesla MRI works in finding cancer in patients with bladder cancer.

What is the current status of trial NCT00938145?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 98 participants. The study started on 2009-07-08. Estimated completion is 2026-12-31.

What conditions does trial NCT00938145 study?

This clinical trial studies the following conditions: Bladder Cancer.

What interventions are being tested in trial NCT00938145?

The interventions under investigation include: Specimen Ultra-High field MRI (PROCEDURE), chemotherapy (DRUG), Cystectomy and Lymphadenectomy (PROCEDURE).

Who is sponsoring clinical trial NCT00938145?

This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00938145 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Bladder Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00938145's enrollment target sits among peer trials

98 88th of 175 higher than 88 of 175 other Bladder Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02926729 · 98 participants · NA

    Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy

  • NCT03382977 · 98 participants · Phase 1

    Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

  • NCT04577014 · 98 participants · Phase 1

    Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

  • NCT04817618 · 98 participants · Phase 3

    Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT00938145, the US trial registry maintained by the National Library of Medicine. NCT00938145 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.